Murphy S, Litwin S, Herring L M, Koch P, Remischovsky J, Donaldson M H, Evans A E, Gardner F H
Am J Hematol. 1982 Jun;12(4):347-56. doi: 10.1002/ajh.2830120406.
In an attempt ot determine the indications for platelet transfusion in thrombocytopenic patients, we randomized 56 children with acute leukemia to one of two regimens of platelet transfusion. The prophylactic group received platelets when the platelet count fell below 20,000 per mm3 irrespective of clinical events. The therapeutic group was transfused only when significant bleeding occurred and not for thrombocytopenia alone. The time to first bleeding episode was significantly longer and the number of bleeding episodes were significantly reduced in the prophylactic group. The survival curves of the two groups could not be distinguished from each other. Prior to the last month of life, the total number of days on which bleeding was present was significantly reduced by prophylactic therapy. However, in the terminal phase (last month of life), the duration of bleeding episodes was significantly longer in the prophylactic group. This may have been due to a higher incidence of immunologic refractoriness to platelet transfusion. Because of this terminal bleeding, comparison of the two groups for total number of days on which bleeding was present did not show a significant difference over the entire study period.
为了确定血小板减少症患者血小板输注的指征,我们将56例急性白血病患儿随机分为两种血小板输注方案中的一组。预防性治疗组在血小板计数降至每立方毫米20,000以下时输注血小板,而不考虑临床事件。治疗性治疗组仅在发生严重出血时才进行输注,而不仅仅因为血小板减少。预防性治疗组首次出血事件的发生时间明显更长,出血事件的数量明显减少。两组的生存曲线无法区分。在生命的最后一个月之前,预防性治疗显著减少了出血天数的总数。然而,在终末期(生命的最后一个月),预防性治疗组的出血事件持续时间明显更长。这可能是由于对血小板输注免疫不应答的发生率较高。由于这种终末期出血,在整个研究期间,两组出血天数总数的比较没有显示出显著差异。